Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
GeneFerm Biotechnology Co., Ltd. specializes in the development and manufacturing of biopharmaceuticals, particularly focusing on recombinant proteins and monoclonal antibodies. The company operates primarily in Taiwan and has established a competitive edge through its proprietary fermentation technology, which enhances yield and reduces production costs.
GeneFerm generates revenue primarily through the sale of biopharmaceutical products, leveraging its proprietary fermentation technology for cost-effective production. The company also engages in contract manufacturing for other biotech firms, providing additional revenue stability. Its competitive advantages include a robust R&D pipeline and strategic partnerships with major pharmaceutical companies.
Regulatory approvals for new drug candidates
Partnership announcements with larger pharmaceutical companies
Changes in biopharmaceutical pricing regulations
Market demand for recombinant proteins and monoclonal antibodies
Regulatory changes impacting drug approval processes
Technological advancements by competitors that could render current products obsolete
Emergence of new biotech firms with innovative technologies
Pricing pressure from generic drug manufacturers
Low return on equity (2.0%) may limit growth potential
Dependence on a few key products for revenue generation
moderate - The biopharmaceutical industry is somewhat insulated from economic downturns, but overall healthcare spending can be affected by GDP growth.
Interest rates affect GeneFerm's cost of capital for R&D and expansion projects. Higher rates could compress margins and reduce investment in new technologies.
minimal - GeneFerm's low debt levels (Debt/Equity of 0.41) indicate limited reliance on credit markets.
growth - Investors seeking exposure to high-growth biotech firms will find GeneFerm appealing due to its strong revenue growth and innovative product pipeline.
high - The stock has shown significant price fluctuations, evidenced by a 1-year return of -22.8%, indicating high volatility.
